Adjusted daily closes · 252 observations · as of Nov 6, 2026
Historical data, not a forecast
1 month
+35.4%
3 months
+28.8%
6 months
+42.3%
1 year
+22.3%
Year to date
+17.7%
52-week range
$4.43 – $8.91
Fundamental snapshot
Latest reported period: Sep 30, 2026
Sharadar reported data
Market cap
$3.06B
P/E
-3.6
P/B
-2.3
P/S
0.3
Revenue
$11.11B
Net income
-$841M
Diluted EPS
-2.29
Gross margin
72.60%
Net margin
-7.60%
Return on equity
58.90%
Total debt
$20.72B
Cash
$2.49B
Free cash flow
$1.83B
Latest eight reported quarters
Reported quarterly values, newest first
Period
Revenue
Net income
Gross margin
Net margin
Free cash flow
Sep 30, 2026
$2.94B
$436M
75.00%
14.80%
$748M
Jun 30, 2026
$2.85B
$258M
72.90%
9.00%
$593M
Mar 31, 2026
$2.52B
-$1.42B
70.80%
-56.40%
$83M
Dec 31, 2025
$2.8B
-$112M
71.50%
-4.00%
$403M
Sep 30, 2025
$2.68B
$179M
72.00%
6.70%
$314M
Jun 30, 2025
$2.53B
$148M
69.80%
5.80%
$189M
Mar 31, 2025
$2.26B
-$58M
69.00%
-2.60%
$87M
Dec 31, 2024
$2.56B
$93M
71.60%
3.60%
$494M
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Bausch Health Companies Inc. raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting a 53% jump in third-quarter adjusted earnings per share to $1.77, significantly beating analyst expectations. Revenue also climbed 10% to $2.941 billion, surpassing estimates, and net income more than doubled. The company also announced a $50 million share buyback program and noted that its Adjusted EBITDA excluding Bausch + Lomb exceeded $1 billion for the first time.
Bausch Health Companies reported strong third-quarter results, exceeding $1 billion in quarterly adjusted EBITDA for the first time and marking 14 consecutive quarters of growth. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted cash flow, driven by strong performance in Salix, International, and Solta Medical segments. Management also discussed debt reduction efforts, capital allocation, and future strategic priorities, including pipeline development and operational excellence, while acknowledging anticipated Q4 headwinds related to Xifaxan.